Red Star in the North. Communism in the Nordic Countries

by Jesper Jørgensen
Published 2016-10-01

Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate

by Jesper Jørgensen, Panos Kefalas
Published 2019-01-01

Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test

by Jesper Jørgensen, Panos Kefalas
Published 2017-01-01

Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries

by Jesper Jørgensen, Eve Hanna, Panos Kefalas
Published 2020-01-01

Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching

by Jesper Jørgensen, Laura Mungapen, Panos Kefalas
Published 2019-01-01

The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’...

by Jesper Jørgensen, Spiros Servos, Panos Kefalas
Published 2018-01-01

Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy

by Panos Kefalas, Omar Ali, Jesper Jørgensen, Nick Merryfield, Tim Richardson, Adam Meads, Laura Mungapen, Matthew Durdy
Published 2018-01-01